Linda Lifetech, an eight-year-old healthtech that moved its headquarters from São Paulo to Toronto, has built a proprietary technology aimed at the early detection of breast cancer and already holds Anvisa clearance in Brazil. In a 2023 clinical trial involving 322 women across three Brazilian states, the solution demonstrated efficacy, underpinning the company’s push for wider regulatory acceptance. The business currently earns about R$12 million in annual revenue by selling to governments, hospitals, private clinics, insurers and pharmacy chains such as Grupo DPSP and Rede Pró-Vida. Fresh capital will allow Linda to seek FDA and Health Canada approvals and to launch a three-year clinical study with the Princess Margaret Cancer Centre, the world’s fifth-largest cancer-research hospital. Participation in the Creative Destruction Lab accelerator, backing from the Canadian Cancer Society and an agreement to test its device in three Swiss cantons further strengthen its clinical and commercial positioning. Over the next two years, management aims to consolidate its Brazilian footprint and open the North American market before pursuing an estimated R$30 million Series A round. The company’s post-seed runway now extends to 24 months, giving it operational stability and resources to execute these milestones.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2026